CN106620269A - Pharmaceutical composition for preventing and treating vitreous opacity and preparation method thereof - Google Patents

Pharmaceutical composition for preventing and treating vitreous opacity and preparation method thereof Download PDF

Info

Publication number
CN106620269A
CN106620269A CN201611133200.XA CN201611133200A CN106620269A CN 106620269 A CN106620269 A CN 106620269A CN 201611133200 A CN201611133200 A CN 201611133200A CN 106620269 A CN106620269 A CN 106620269A
Authority
CN
China
Prior art keywords
ethanol
extract
pharmaceutical composition
herb
weight portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201611133200.XA
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Haoyu Qingtian Medicine Technology Co ltd
Original Assignee
Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Haoyu Qingtian Medicine Technology Co ltd filed Critical Jinan Haoyu Qingtian Medicine Technology Co ltd
Priority to CN201611133200.XA priority Critical patent/CN106620269A/en
Publication of CN106620269A publication Critical patent/CN106620269A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/89—Cyperaceae (Sedge family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a pharmaceutical composition for preventing and treating vitreous opacity and a preparation method thereof. The pharmaceutical composition disclosed by the invention is prepared by matching the following crude drugs: crake, oberonia iridifolia, asiaticoside, fimbristylis dichotoma and hedyotis capituligera can be prepared into various dosage forms according to conventional preparation processes. The pharmaceutical composition has an obvious curative effect in prevention and treatment for vitreous opacity.

Description

A kind of pharmaceutical composition of preventing and treating vitreous opacity and preparation method thereof
Technical field
The invention belongs to technical field of traditional Chinese medicines, more particularly to a kind of pharmaceutical composition and its preparation of preventing and treating vitreous opacity Method.
Background technology
Vitreous opacity (vitreous opacities) is not name of disease but a kind of modal phenomenon of vitreum.It is various Eye illness can cause vitreous opacity, most commonly senile degeneration, Myopia change, posterior detachment of vitreous and physiological to fly Mosquito disease, in addition detachment of retina, uveitis, primary familial amyloidosis, synchysis scintillans etc. also can go out The clinical manifestations such as existing muscae genetic vision.Vitreum is transparent gelatinous tissue, is clearly become clear, and it can make vitreous gel performance steady It is fixed, ensure that vitreum and its retina of surrounding are buffered in Rotation of eyeball or when being shaken.And clearly have no time in the visual field, protect The acuity of eyesight is demonstrate,proved.If occurring in that the opaque body in addition to normal configuration, referred to as vitreous opacity in glass body. Its main clinic symptoms has:Morbidity is unexpected, often has repeatedly.Occur column of smoke formula or black clouds shape shadow at the moment, what is had is blind quickly, only Stay light sensation.Main physical signs are:See in glass body there is cerise clot under slit-lamp, or the outmoded bleeding of brown color.See under ophthalmoscope Dirt shape, strip and block muddiness are floated, or rarely seen dilute micro- ruddiness, or without ruddiness.Repeated Hemorrhage person, visible proliferative in glass body Bar rope or film, with new vessels.Corticosteroid hormone, hemostasis, anti-freezing, enzyme preparation, Operand, calcium are adopted modern medicine more Agent, ultrasonic wave, sodium iodide current iontophoresis, laser and vitrectomy etc. are treated, but can not be using ultrasound to fresh focus Ripple, laser and operation etc. are treated；Especially patient with slight symptoms is reluctant to be treated surgically most of patient, therefore necessary searching New effective treatment method.
Iris-leaf oberonia herb：This product is orchid family iris epidendrum iris orchid Oberonia iridifolia (Roxb.) Lindl. The herb of [Cymbidium iridifolium Roxb.].Whole year can harvest, and boiling water is dried after scalding.【Nature and flavor】Slight bitter；Property It is cool.【Return through】Bladder warp.【Indication】Clearing heat and promoting diuresis；It is promoting blood circulation and removing obstruction in channels.Main urinary tract infections；Bronchitis；Asthma；Enteritis； Indigestion；Traumatic injury；Fracture.【Former phytomorph】Iris is blue, perennial draft of growing nonparasitically upon another plant, high 12-30cm, the most palpuses of cluster life Root.Leaf is thick, and both sides are flattened and mutual intussusception, sword-shaped or long round shape lanceolar, and long 4-13cm, wide 1-2cm, tip is sometimes slightly askew Tiltedly, base portion has joint.Raceme is extracted out from plant center, is longer than leaf, uprightly, cylinder, the most intensive little Hua of tool；It is little The thin keratin of bract, avette, long 1.5-2mm.Spend little, diameter about 2mm, white green；Sepal and the equal reflexed of petal, petal compares sepal It is narrow；Lip is closely semicircle, and shape is closely eroded at edge, and tip 2 splits.Capsule falls ovate-elliptic, is about 5mm, the long 1.5mm of handle.Florescence The 10-11 months, the fruiting period 11-12 month.Record in dictionary of medicinal plant.
Water rail：This product is the meat that Rallidae water rail belongs to animal water rail Rallus apuaticus (Linnaeus).The four seasons are equal Can catch, after catching, remove feather and internal organ, take meat.【Nature and flavor】It is sweet；It is warm in nature.【Return through】Large intestine channel.【Indication】Removing toxic substances Desinsection；Tonifying middle-Jiao and Qi.Main ant fistula；It is weakness of the spleen and the stomach；Poor appetite.【Former zoomorphism】Water rail, body is about 30cm.It is little；Neck It is long.Upper body feather taupe, band black speckle, head speckle is particularly significant.The more than half ash of two wing surfaces is brown.Lower body brown, two Armpit has hickie；Crissum is identical with lower tall coverts black and white, plumage end white.Shin plumage is black and has white horizontal spot.Mouth is dark brown, lower mouth base portion compared with It is light.Pin sepia.Record in dictionary of medicinal plant.
Dichotomous fimbristylis herb：For qi dichotomous fimbristylis herb Fimbristylis dichotoma (L) Vahl of Cyperaceae genus fimbristylis plant two [Scirpus dichotomus L.;S.annuus All.;Fimbristylis annua(All.)Roem.et Schult] Herb.Summer, autumn harvesting, clean, and dry.【Nature and flavor】It is lightly seasoned；It is cold in nature.【Return through】Kidney；Bladder warp.【Indication】Heat-clearing profit Urine；Removing toxic substances.Main difficult urination；Damp and hot edema；Gonorrhoea；Infant fetal toxin.【Chemical analysis】Containing dihydrocyperaquinone (dihydrooyperaqnone), tetrahydrocyperaquinone.(tetrahydrocyperaquinone), cyperaquinone (cyperapuinone), hydroxyl cyperaquinone (hydroxycyperapuinone), removes first cyperaquinone (demethylcyperapuinone).【Former phytomorph】Not tally dichotomous fimbristylis herb, draft.Stalk is grown thickly, high 20-50cm.Complete stool without Hair has thin pubescence.Leaf is linear, is shorter than stalk, and wide 1-2.5mm, tip is suddenly sharp or blunt；Sheath base portion keratin.Lobate bract under inflorescence 3-4, normal 1-2 pieces, is longer than inflorescence.Cyme is appeared again or simply；Small ear is avette or long round shape is avette, long 5-12mm, wide 2- 3mm, there is most flowers；Scale is avette or Long Circle, long 2-2.5mm, and sepia is glossy, there is 3-5 arteries and veins, and tip has short point；Stamen 2-3；Style is flat, and echinid is arranged at top；Column cap 2.Pyrene width obovate, biconvex shape, long 1-1.2mm, white to filbert, Surface is grown crosswise circular reticulate pattern, and longitudinal rib 7-9 bar, significant protuberance has brown short handle.Flower, the fruiting period 7-10 month.Record diction big in Chinese medicine Allusion quotation.
Common anotis herb：For Rubiaceae vacation plants of Hedyotis common anotis herb Anotis ingrata (wall.) Hook. F. The herb of [Neanotis yngrata (Wall.ex Hook .f) W.H.Lewis].Summer, autumn receive adopt herb, eliminate soil, Debris, dry standby.【Nature and flavor】Taste is pungent；It is cool in nature.【Return through】The heart；Liver Channel.【Indication】Clearing liver-fire.Main nameless sores or boils；Mesh It is crimson swollen；Venomous snake bite.【Former phytomorph】Renascent herb, up to 1m.Stem branch or does not have minority branch, it is upright or under The sleeping ground in portion.Leaf opposite；Petiole is short；The nearly triangle in stipule bottom, Colaesce is born between two petioles, edge tool fine hair；Blade , to ovum shape lanceolar, long 4-9cm, wide about 1.8cm, tip is tapering, base portion wedge shape, full edge for papery, oval or long oval, Two sides is by pubescence.Dichasium basidixed, total bennet and branch have narrow aliform corner angle；Floral white, without obstructing or have short Stalk；Calyx 4 splits, sliver triangular shape lanceolar, and corolla is about 5mm, and hat manages slightly wider, interior raw pubescence；Stamen 4, flower pesticide exposes corolla Outward；Ovary is the next, and Room 2, column cap 2 splits.Capsule is subsphaeroidal, slightly flat-sided, wide about 2mm.Seed is little and most, plano-convex, there is little wart point. The month at florescence 6-7, the fruiting period 7-8 month.Record in dictionary of medicinal plant.
Asiaticosid（Asiaticoside）：CAS 16830-15-2, molecular formula C48H78O19, molecular weight 959.12.【It is raw Thing activity】Promote wound healing.【Ingredient origin】Centella Centella asiatica.
1 bulk drug chemical constitution：
Asiaticosid（Asiaticoside）.
The content of the invention
The purpose of the present invention is to overcome the shortcomings of background technology, there is provided a kind of drug regimen of effective preventing and treating vitreous opacity Thing and preparation method thereof.
The present invention adopts the following technical scheme that realization：
The composition and weight portion for making the bulk drug of the pharmaceutical composition of the preventing and treating vitreous opacity be：
Water rail 86-88 weight portion iris-leaf oberonia herb 60-64 weight portion asiaticosid 1-1.2 weight portion dichotomous fimbristylis herb 50-52 weight portions Common anotis herb 30-36 weight portions.
The pharmaceutical composition of preventing and treating vitreous opacity is preferably used in, is made up of the bulk drug of following weight portion：
The weight of 51 weight portion common anotis herb of water rail 87 weight portion iris-leaf oberonia herb, 62 weight portion asiaticosid, 1.1 weight portion dichotomous fimbristylis herb 33 Part.
A kind of pharmaceutical composition of preventing and treating vitreous opacity, it is characterised in that pharmaceutical composition can adopt the normal of galenic pharmacy Rule method prepares piece agent or capsule or dripping pill.
A kind of pharmaceutical composition of preventing and treating vitreous opacity, it is characterised in that pharmaceutical composition is constituted with chemical drugs or Chinese medicine Preventing and treating vitreous opacity medicine.
A kind of preparation method of the pharmaceutical composition of preventing and treating vitreous opacity, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：Water rail 86-88 weight portion iris-leaf oberonia herb 60-64 weight portion asiaticosids 1-1.2 weights Amount part dichotomous fimbristylis herb 50-52 weight portion common anotis herb 30-36 weight portions；
Preparation method：
（1）By bulk drug proportioning seedling taking chicken, iris-leaf oberonia herb, asiaticosid, dichotomous fimbristylis herb, common anotis herb, mix, use weight percent concentration 34.5% ethanol takes as solvent in 26 DEG C of temperature extractions, and extraction time is 37 times, and each extraction time is 18 hours, each solvent Consumption is 50 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative density 1.10, filtration, liquid is first washed with water by HPD500 large pore resin absorption columns, then molten with the ethanol of weight percent concentration 19% Liquid wash-out HPD500 large pore resin absorption columns, the collection ethanol eluate of weight percent concentration 19%, recovery ethanol, concentrate drying, Obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 57% as solvent, heating and refluxing extraction 19 times, carries every time The time is taken for 0.3 hour, each solvent load is 23 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned Ethanol is received, relative density 1.15 is concentrated into, is filtered, liquid is first washed with water by DM-7HP large pore resin absorption columns, then with again Amount percent concentration 86% ethanol solution wash-out DM-7HP large pore resin absorption columns, collect the ethanol elution of weight percent concentration 86% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
The preparation method of the pharmaceutical composition of preferred a kind of preventing and treating vitreous opacity, it is characterised in that make as follows It is standby：
The composition and weight portion of bulk drug be：The weight portion of 87 weight portion iris-leaf oberonia herb of water rail, 62 weight portion asiaticosid 1.1 moves swiftly The careless weight portion of 51 weight portion common anotis herb 33；
Preparation method：
（1）By bulk drug proportioning seedling taking chicken, iris-leaf oberonia herb, asiaticosid, dichotomous fimbristylis herb, common anotis herb, mix, use weight percent concentration 34.5% ethanol takes as solvent in 26 DEG C of temperature extractions, and extraction time is 37 times, and each extraction time is 18 hours, each solvent Consumption is 50 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative density 1.10, filtration, liquid is first washed with water by HPD500 large pore resin absorption columns, then molten with the ethanol of weight percent concentration 19% Liquid wash-out HPD500 large pore resin absorption columns, the collection ethanol eluate of weight percent concentration 19%, recovery ethanol, concentrate drying, Obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 57% as solvent, heating and refluxing extraction 19 times, carries every time The time is taken for 0.3 hour, each solvent load is 23 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned Ethanol is received, relative density 1.15 is concentrated into, is filtered, liquid is first washed with water by DM-7HP large pore resin absorption columns, then with again Amount percent concentration 86% ethanol solution wash-out DM-7HP large pore resin absorption columns, collect the ethanol elution of weight percent concentration 86% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
A kind of preparation method of the pharmaceutical composition of preventing and treating vitreous opacity, it is characterised in that pharmaceutical composition can be adopted The conventional method of galenic pharmacy prepares piece agent or capsule or dripping pill.
A kind of preparation method of the pharmaceutical composition of preventing and treating vitreous opacity, it is characterised in that pharmaceutical composition and chemical drugs Or Chinese medicine composition preventing and treating vitreous opacity medicine.
Pharmaceutical composition preventing and treating vitreous opacity is evident in efficacy.
Specific embodiment
Embodiment 1：Pharmaceutical composition of preventing and treating vitreous opacity and preparation method thereof
Preventing and treating vitreous opacity pharmaceutical composition bulk drug composition and weight portion be：Water rail 87g iris-leaf oberonia herb 62g accumulated snow Careless glycosides 1.1g dichotomous fimbristylis herbs 51g common anotis herb 33g；
Preparation method：
（1）By bulk drug proportioning seedling taking chicken, iris-leaf oberonia herb, asiaticosid, dichotomous fimbristylis herb, common anotis herb, mix, use weight percent concentration 34.5% ethanol takes as solvent in 26 DEG C of temperature extractions, and extraction time is 37 times, and each extraction time is 18 hours, each solvent Consumption is 50 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative density 1.10, filtration, liquid is first washed with water by HPD500 large pore resin absorption columns, then molten with the ethanol of weight percent concentration 19% Liquid wash-out HPD500 large pore resin absorption columns, the collection ethanol eluate of weight percent concentration 19%, recovery ethanol, concentrate drying, Obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 57% as solvent, heating and refluxing extraction 19 times, carries every time The time is taken for 0.3 hour, each solvent load is 23 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned Ethanol is received, relative density 1.15 is concentrated into, is filtered, liquid is first washed with water by DM-7HP large pore resin absorption columns, then with again Amount percent concentration 86% ethanol solution wash-out DM-7HP large pore resin absorption columns, collect the ethanol elution of weight percent concentration 86% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 2：Pharmaceutical composition of preventing and treating vitreous opacity and preparation method thereof
Preventing and treating vitreous opacity pharmaceutical composition bulk drug composition and weight portion be：Water rail 86g iris-leaf oberonia herb 64g accumulated snow Careless glycosides 1g dichotomous fimbristylis herbs 52g common anotis herb 30g；
Preparation method：
（1）By bulk drug proportioning seedling taking chicken, iris-leaf oberonia herb, asiaticosid, dichotomous fimbristylis herb, common anotis herb, mix, use weight percent concentration 34.5% ethanol takes as solvent in 26 DEG C of temperature extractions, and extraction time is 37 times, and each extraction time is 18 hours, each solvent Consumption is 50 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative density 1.10, filtration, liquid is first washed with water by HPD500 large pore resin absorption columns, then molten with the ethanol of weight percent concentration 19% Liquid wash-out HPD500 large pore resin absorption columns, the collection ethanol eluate of weight percent concentration 19%, recovery ethanol, concentrate drying, Obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 57% as solvent, heating and refluxing extraction 19 times, carries every time The time is taken for 0.3 hour, each solvent load is 23 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned Ethanol is received, relative density 1.15 is concentrated into, is filtered, liquid is first washed with water by DM-7HP large pore resin absorption columns, then with again Amount percent concentration 86% ethanol solution wash-out DM-7HP large pore resin absorption columns, collect the ethanol elution of weight percent concentration 86% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 3：Pharmaceutical composition of preventing and treating vitreous opacity and preparation method thereof
Preventing and treating vitreous opacity pharmaceutical composition bulk drug composition and weight portion be：Water rail 88g iris-leaf oberonia herb 60g accumulated snow Careless glycosides 1.2g dichotomous fimbristylis herbs 50g common anotis herb 36g；
Preparation method：
（1）By bulk drug proportioning seedling taking chicken, iris-leaf oberonia herb, asiaticosid, dichotomous fimbristylis herb, common anotis herb, mix, use weight percent concentration 34.5% ethanol takes as solvent in 26 DEG C of temperature extractions, and extraction time is 37 times, and each extraction time is 18 hours, each solvent Consumption is 50 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative density 1.10, filtration, liquid is first washed with water by HPD500 large pore resin absorption columns, then molten with the ethanol of weight percent concentration 19% Liquid wash-out HPD500 large pore resin absorption columns, the collection ethanol eluate of weight percent concentration 19%, recovery ethanol, concentrate drying, Obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 57% as solvent, heating and refluxing extraction 19 times, carries every time The time is taken for 0.3 hour, each solvent load is 23 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned Ethanol is received, relative density 1.15 is concentrated into, is filtered, liquid is first washed with water by DM-7HP large pore resin absorption columns, then with again Amount percent concentration 86% ethanol solution wash-out DM-7HP large pore resin absorption columns, collect the ethanol elution of weight percent concentration 86% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 4：The preparation of tablet
The pharmaceutical composition 230g of Example 1, adds starch 360g, mixes, and granulation is dried, plus microcrystalline cellulose 200g, stearic Sour magnesium 10g, mixes, and is pressed into 2000, obtains final product medicinal composition tablets.
Embodiment 5：The preparation of capsule
The pharmaceutical composition 144g of Example 2, adds starch 242g, mixes, and granulation is dried, whole grain, adds appropriate stearic acid Magnesium, mixes, and encapsulated 900, obtains final product medicament composition capsule.
Embodiment 6：The preparation of dripping pill
Weigh (80 DEG C) heating of Macrogol 6000 108g water-baths and boil molten, add the pharmaceutical composition 4.3g of embodiment 3, fully stir Mix uniform, with atoleine as cooling agent, put glass tube（4*80cm）In, chilling temperature is -5 DEG C, and drip internal-and external diameter is 7.0/ 2.0 (mm/mm), drip is 2.4cm away from liquid level, and drop speed, as optimum condition, with cotton the cold of dripping pill surface is blotted with per point 48 drops Solidifying agent, obtains final product medicament composition dropping pills.
Embodiment 7：The pharmaceutical composition of preventing and treating vitreous opacity
Preventing and treating vitreous opacity pharmaceutical composition bulk drug composition and weight portion be：
The weight portion of 83 weight portion dichotomous fimbristylis herb of water rail, 65 weight portion common anotis herb 40.
Embodiment 8：The pharmaceutical composition of preventing and treating vitreous opacity
Preventing and treating vitreous opacity pharmaceutical composition bulk drug composition and weight portion be：
The weight portion of 2 weight portion dichotomous fimbristylis herb of asiaticosid, 36 weight portion common anotis herb 50.
Embodiment 9：The pharmaceutical composition of preventing and treating vitreous opacity
Preventing and treating vitreous opacity pharmaceutical composition bulk drug composition and weight portion be：
The weight portion of 4 weight portion dichotomous fimbristylis herb of asiaticosid, 50 weight portion common anotis herb 45.
Experimental example 1：The experimental study of preventing and treating vitreous opacity
1 data and method
1.1 case-data
City's hospital outpatient and inpatient department amount to 44 66 vitreums and mix during being collected from June, 2012 in May, 2013 altogether Turbid patient, wherein man 24, female 20, age 20-74 year.Simple eye 22, eyes 22, the cause of disease that vitreous opacity occurs: Moderate and high myopia；Traumatic hematocele, diabetic keratopathy bleeding, Retinopathy of Hypertension.All patients meet following standard: （1）Feel there is shadow at the moment, shape differs, dense or light, erratic motion during Rotation of eyeball.（2）The lighter does not affect one's power of vision, weight Person affects one's power of vision.（3）Eyeground transillumination is checked:When making the tested eye of patient rotate up and down, it is seen that black or have it is translucent it Point-like, strip, block muddiness are waved.（4）Slit-lamp adds its position of preset lens observable and proterties.（5）Make eye ultrasound if necessary Check and visual electrophsiology inspection, understand the property and retina situation of vitreous opacity.It is divided into two groups by random digits table, its Middle treatment group 22 33, control group 22 33.Situations such as two groups of patient ages, sex, state of an illness are distributed is compared without significantly Sex differernce, with comparativity.
1.2 treatment method
Two groups take the cause of disease, suit the medicine to the illness, supporting treatment:If any traumatic vitreous hemorrhage person, give and stop blooding, promote blood absorption Deng treatment；If any intraocular inflammation person, anti-inflammatory treatment is given；Cure the Primary Disease.Other treatment group:Combination of oral medication (pharmaceutical composition of embodiment 1), 2g/ time, 2 times a day.Control group:Oral Qiju Dihuang Wan (production of Beijing Tongrentang), 9g/ Secondary, 2 times a day.Two groups are continuously treated 3 months, further consultation every month 1 time, and to follow-up of patients to 6th month.
1.3 the standard of curative effect evaluation
Observation index:Treatment before and treatment 3 months after row slit-lamp, ophthalmoscope and eye test respectively, observe Different therapeutical effect, lead to Cross ultrasonic examination vitreous opacity absorbing state.Vitreous opacity presses standard level Four point-score:1 grade:Vitreous opacity but do not affect Fundus observation；2 grades:Eyeground reflection to red light substantially, dim can be got a glimpse of regarding nipple and blood vessel；3 grades:There is reflection to red light on eyeground, sees not See optical fundus blood vessel；4 grades:Lesser ring of Merkel has reflection to red light.Curative effect determinate standard:Efficacy evaluation is with reference to directly funduscopy after mydriasis And eye test result as a result.It is effective:Vitreous opacity substantially absorbs, and primary affection is controlled, and symptom disappears, and eyesight improves 5 More than row, vitreous opacity is high-visible to eyeground by 2 level restorations by 3 grades to 1 grade by 4 grades to 2 grades；Effectively:Vitreum is mixed It is turbid to partially absorb, symptom mitigation, eyesight improve 2-5 rows, vitreous opacity by 4 grades to 3 grades, by 3 grades to 2 grades；It is invalid:Vitreum Muddiness is unchanged or increases, and, without improvement, eyesight is without improve for symptom.Survey body temperature, breathing, arteries and veins before and after each patient's treatment in addition Fight, the general indicator such as blood pressure, and blood, urine, feces routine test, security is evaluated in Liver and kidney function and Electrocardioscopy.
1.4 statistical method
Analyzed using EPITABLE statistical softwares.Enumeration data adopts Chi-square Test, P<0.05 indicates significant difference.
2 results
2.1 comparitive study
The results are shown in Table 1.
The treatment results of each group of table 1
Group N (eye) It is effective Effectively It is invalid Obvious effective rate (%) Total effective rate (%)
Treatment group 33 18 14 1 54.55* 96.97*
Control group 33 12 13 8 36.36 75.76
*:P<0.05, compared with control group, there is significant difference.
2. 2 bad reactions are compared
Before and after treatment group and treatment of control group there is no obvious ANOMALOUS VARIATIONS in safety indexes.

Claims (8)

1. it is a kind of preventing and treating vitreous opacity pharmaceutical composition, it is characterised in that make the composition of the bulk drug of the pharmaceutical composition It is with weight portion：
Water rail 86-88 weight portion iris-leaf oberonia herb 60-64 weight portion asiaticosid 1-1.2 weight portion dichotomous fimbristylis herb 50-52 weight portions Common anotis herb 30-36 weight portions.
2. according to claim 1 it is a kind of preventing and treating vitreous opacity pharmaceutical composition, it is characterised in that make the medicine group The composition and weight portion of the bulk drug of compound be：
The weight of 51 weight portion common anotis herb of water rail 87 weight portion iris-leaf oberonia herb, 62 weight portion asiaticosid, 1.1 weight portion dichotomous fimbristylis herb 33 Part.
3. according to claim 1 it is a kind of preventing and treating vitreous opacity pharmaceutical composition, it is characterised in that pharmaceutical composition can To prepare piece agent or capsule or dripping pill using the conventional method of galenic pharmacy.
4. according to claim 1 it is a kind of preventing and treating vitreous opacity pharmaceutical composition, it is characterised in that pharmaceutical composition with The preventing and treating vitreous opacity medicine of chemical drugs or Chinese medicine composition.
5. it is a kind of preventing and treating vitreous opacity pharmaceutical composition preparation method, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：Water rail 86-88 weight portion iris-leaf oberonia herb 60-64 weight portion asiaticosids 1-1.2 weights Amount part dichotomous fimbristylis herb 50-52 weight portion common anotis herb 30-36 weight portions；
Preparation method：
（1）By bulk drug proportioning seedling taking chicken, iris-leaf oberonia herb, asiaticosid, dichotomous fimbristylis herb, common anotis herb, mix, use weight percent concentration 34.5% ethanol takes as solvent in 26 DEG C of temperature extractions, and extraction time is 37 times, and each extraction time is 18 hours, each solvent Consumption is 50 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative density 1.10, filtration, liquid is first washed with water by HPD500 large pore resin absorption columns, then molten with the ethanol of weight percent concentration 19% Liquid wash-out HPD500 large pore resin absorption columns, the collection ethanol eluate of weight percent concentration 19%, recovery ethanol, concentrate drying, Obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 57% as solvent, heating and refluxing extraction 19 times, carries every time The time is taken for 0.3 hour, each solvent load is 23 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned Ethanol is received, relative density 1.15 is concentrated into, is filtered, liquid is first washed with water by DM-7HP large pore resin absorption columns, then with again Amount percent concentration 86% ethanol solution wash-out DM-7HP large pore resin absorption columns, collect the ethanol elution of weight percent concentration 86% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
6. according to claim 5 it is a kind of preventing and treating vitreous opacity pharmaceutical composition preparation method, it is characterised in that press It is prepared by following steps：
The composition and weight portion of bulk drug be：The weight portion of 87 weight portion iris-leaf oberonia herb of water rail, 62 weight portion asiaticosid 1.1 moves swiftly The careless weight portion of 51 weight portion common anotis herb 33；
Preparation method：
（1）By bulk drug proportioning seedling taking chicken, iris-leaf oberonia herb, asiaticosid, dichotomous fimbristylis herb, common anotis herb, mix, use weight percent concentration 34.5% ethanol takes as solvent in 26 DEG C of temperature extractions, and extraction time is 37 times, and each extraction time is 18 hours, each solvent Consumption is 50 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, is concentrated into relative density 1.10, filtration, liquid is first washed with water by HPD500 large pore resin absorption columns, then molten with the ethanol of weight percent concentration 19% Liquid wash-out HPD500 large pore resin absorption columns, the collection ethanol eluate of weight percent concentration 19%, recovery ethanol, concentrate drying, Obtain final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 57% as solvent, heating and refluxing extraction 19 times, carries every time The time is taken for 0.3 hour, each solvent load is 23 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned Ethanol is received, relative density 1.15 is concentrated into, is filtered, liquid is first washed with water by DM-7HP large pore resin absorption columns, then with again Amount percent concentration 86% ethanol solution wash-out DM-7HP large pore resin absorption columns, collect the ethanol elution of weight percent concentration 86% Liquid, reclaims ethanol, and concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
7. according to claim 5 it is a kind of preventing and treating vitreous opacity pharmaceutical composition preparation method, it is characterised in that medicine Compositions can adopt the conventional method of galenic pharmacy to prepare piece agent or capsule or dripping pill.
8. according to claim 5 it is a kind of preventing and treating vitreous opacity pharmaceutical composition preparation method, it is characterised in that medicine Compositions and chemical drugs or Chinese medicine composition preventing and treating vitreous opacity medicine.
CN201611133200.XA 2016-12-10 2016-12-10 Pharmaceutical composition for preventing and treating vitreous opacity and preparation method thereof Withdrawn CN106620269A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611133200.XA CN106620269A (en) 2016-12-10 2016-12-10 Pharmaceutical composition for preventing and treating vitreous opacity and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611133200.XA CN106620269A (en) 2016-12-10 2016-12-10 Pharmaceutical composition for preventing and treating vitreous opacity and preparation method thereof

Publications (1)

Publication Number Publication Date
CN106620269A true CN106620269A (en) 2017-05-10

Family

ID=58825426

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611133200.XA Withdrawn CN106620269A (en) 2016-12-10 2016-12-10 Pharmaceutical composition for preventing and treating vitreous opacity and preparation method thereof

Country Status (1)

Country Link
CN (1) CN106620269A (en)

Similar Documents

Publication Publication Date Title
CN102600386A (en) Chinese herba preparation for treating eye inflammation and preparation method of Chinese herba preparation
CN106109564A (en) Pharmaceutical composition for the treatment of cerebral thrombosis and preparation method thereof
CN102552639A (en) Traditional Chinese medicine possessing function for alleviating asthenopia and its preparation method
CN106620269A (en) Pharmaceutical composition for preventing and treating vitreous opacity and preparation method thereof
CN103251725B (en) A kind of application of Chinese medicine composition in treatment keratitis medicine is prepared
CN104740334B (en) It is a kind of to be used to prevent and treat Chinese medicine composition of cataract and preparation method thereof
CN104324139B (en) A kind of pharmaceutical composition treating xerophthalmia
CN106620056A (en) Pharmaceutical composition for treating diabetic retinopathy
CN106581122A (en) Pharmaceutical composition for treating acute cervicitis
CN106728143A (en) Prevent and treat pharmaceutical composition of vitreous opacity and preparation method thereof
CN106539929A (en) It is a kind of to treat pharmaceutical composition of vitreous opacity and preparation method thereof
CN106581220A (en) Pharmaceutical composition for preventing and treating vitreous opacity
CN106728625A (en) A kind of pharmaceutical composition for treating rhinitis
CN106668239A (en) Pharmaceutical composition for preventing vitreous opacity
CN106539934A (en) A kind of pharmaceutical composition for treating optic atrophy
CN106692502A (en) Medicinal composition for preventing and treating optic atrophy
CN106728893A (en) Treat pharmaceutical composition of diabetic retinopathy and preparation method thereof
CN106727851A (en) Prevent and treat pharmaceutical composition of ovarian cyst and preparation method thereof
CN106728624A (en) A kind of pharmaceutical composition for preventing and treating viral pharyngitis and preparation method thereof
CN106728422A (en) It is a kind of to prevent and treat pharmaceutical composition of glaucoma and preparation method thereof
CN106581263A (en) Pharmaceutical composition for treating lumbar disc herniation and preparation method thereof
CN106727820A (en) Prevent and treat the pharmaceutical composition of optic atrophy
CN106668396A (en) Pharmaceutical composition for preventing and treating postpartum bodily pain and preparation method thereof
CN106822340A (en) A kind of pharmaceutical composition of anti-treating cervicitis
CN106668183A (en) Pharmaceutical composition for treating epilepsy and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20170510